Zhejiang Starry Pharmaceutical Co.,Ltd.

603520

CNE1000026N8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
9.29 ^CNY	-0.11%		+1.98%	-34.02%

05-29	Starry Pharma Gets China Nod for MRI Contrast Agent Injectable	MT
05-28	Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding	CI

Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding

May 27, 2024

On May 28, 2024, Zhejiang Starry Pharmaceutical Co.,Ltd., closed the transaction. The company issued a total of 95,895,380 A shares at a price of CNY 9.75 per share for the gross proceeds of CNY 934,979,955.

Latest news about Zhejiang Starry Pharmaceutical Co.,Ltd.

Starry Pharma Gets China Nod for MRI Contrast Agent Injectable	05-29	MT
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding	05-27	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million.	21/08/23	CI
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.	06/07/23	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	15/04/23	CI
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval	23/02/23	MT
Zhejiang Starry Pharma’s CFO Resigns	19/12/22	MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.	15/09/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding	25/08/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/04/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/04/22	CI
Zhejiang Zhumei Import and Export Group Co., Ltd agreed to acquire Zhejiang Xianju Thermal Power Co., Ltd from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 35 million.	29/03/22	CI
Zhejiang Starry Pharmaceutical Co.,Ltd.(SHSE:603520) dropped from Shanghai Stock Exchange Health Care Sector Index	10/12/21	CI
Zhejiang Hisyn Pharmaceutical Co., Ltd. announced that it has received CNY 110.2637 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	29/11/21	CI
Shanghai Yujun Biological Technology Development Co., Ltd. announced that it expects to receive CNY 38 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	25/11/21	CI
Lansen Pharma Offloads Nearly $4 Million Shares in Zhejiang Starry Pharmaceutical	05/11/21	MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/10/21	CI

Chart Zhejiang Starry Pharmaceutical Co.,Ltd.

Duration

Period

Chart Zhejiang Starry Pharmaceutical Co.,Ltd.

More charts

Company Profile

Zhejiang Starry Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceutical specialty raw materials. The Company's business includes the production and sales of intermediates, APIs and preparations of iodine contrast agent series products such as iohexol, iopamidol, iodixanol, iomeprol, ioversol and iopromide. The Company's main products are non-ionic iodine contrast agent series drugs, levofloxacin series products, levofloxacin APIs and intermediates.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Starry Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.29 CNY

Average target price

17.54 CNY

Spread / Average Target

+88.81%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.	-34.02%	562M
ELI LILLY AND COMPANY	+62.57%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.06%	359B
MERCK & CO., INC.	+15.68%	325B
ABBVIE INC.	+8.62%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.61%	177B
PFIZER, INC.	+1.76%	165B

Other Pharmaceuticals